Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285913 | 1.00 | ERN1 (0.59) | ERN1MAPTALDH1A1KDM4ECYP3A4 | |
| SCHEMBL2402093 | 0.84 | GPR35 (0.61) | MAPTALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL11757360 | 0.83 | MAPT (0.54) | ERN1MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL17113788 | 0.82 | MAPT (0.54) | ERN1MAPTALDH1A1KDM4ECYP3A4 | |
| SCHEMBL7285302 | 0.80 | ERN1 (0.62) | ERN1ALDH1A1 | |
| SCHEMBL15199259 | 0.80 | GPR35 (0.56) | MAPTALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL4468567 | 0.78 | MAPT (0.53) | ERN1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL10013940 | 0.78 | GPR35 (0.69) | ERN1MAPT | |
| SCHEMBL4437002 | 0.77 | ERN1 (0.55) | ERN1MAPTALDH1A1KDM4ECYP3A4 | |
| SCHEMBL13144730 | 0.77 | MAPT (0.49) | ERN1MAPTALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843515-A | Aromatic amino acid derivative as LAT1 inhibitor and preparation method and application thereof | 中国药科大学 | 2024-04-09 | — | — | CN | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| WO-2014183300-A1 | VEGFR TYROSINE KINASE INHIBITORS | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO., LTD. (CN) | 2014-11-20 | — | — | WO | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| EP-0385407-B1 | A photochromic material | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1994-11-23 | — | — | EP | disclosed |
| EP-0411885-B1 | Novel photochromic spiropyran compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1994-09-07 | — | — | EP | disclosed |
| EP-0389813-B1 | A method for preparing a photochromic material | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5241075-A | Long wavelength absorption sensitivity; for use with semiconductor lasers | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5155230-A | PHOTOCHROMIC DINITRATED SPIROPYRANS | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5095120-A | Halogenation | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-03-10 | — | — | US | disclosed |
| EP-0414476-A1 | Process for the preparation of photochromic spiropyran compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| EP-0411885-A1 | Novel photochromic spiropyran compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
| EP-0389813-A1 | A method for preparing a photochromic material | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |
| EP-0385407-A2 | A photochromic material | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | ERN1 1611/4885MAPT 4120/4885ALDH1A1 2771/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | ERN1 2670/4885MAPT 4253/4885ALDH1A1 1004/4885 |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | ERN1 787/4885MAPT 4195/4885ALDH1A1 1267/4885 |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | ERN1 3192/4885MAPT 387/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.